DocumentRX-9808
Issued
Read4 min

J&J Pays $2.2 Billion for Ollin, Mounting Direct Challenge to Roche's Vabysmo

J&J will acquire Ollin Biosciences for $2.2 billion, gaining OLN324, a VEGF/Ang2 bispecific that beat Vabysmo on structural endpoints in Phase 1b. Blackstone funds Phase 3.

TAG K-8919 · 703 words on the filing

J&J’s $2.2B Ollin Buyout Brings Late-Stage Eye Drug; Blackstone Deal Adds Trial Funding
J&J’s $2.2B Ollin Buyout Brings Late-Stage Eye Drug; Blackstone Deal Adds Trial Fundingkfuhlert / pixabay

Summary of findings

  • J&J agreed on Monday to acquire Ollin Biosciences for $2.2 billion: $1.2 billion upfront plus up to $1.1 billion in OLN324 milestones; closing expected by year-end.
  • In head-to-head Phase 1b, OLN324 produced faster, greater structural changes and numerically better vision gains than Roche's Vabysmo at 20 weeks in AMD and DME.
  • Blackstone Life Sciences will pay up to $750 million for late-stage development in exchange for milestones and royalties.
  • Ollin launched with $100 million from Arch, Mubadala and Monograph; a $330 million Series B co-led by TCGX and Arch closed in June.
  • The deal adds OLN102, a TSHR/IGF-1R bispecific for thyroid eye disorder, expected to enter the clinic this year.

Johnson & Johnson will pay $2.2 billion to acquire Ollin Biosciences, securing a late-stage bispecific antibody that goes straight at Roche's Vabysmo franchise. The company announced the agreement on Monday. Separately, Blackstone Life Sciences has agreed to fund up to $750 million of the drug's pivotal-stage development in exchange for regulatory and sales milestones plus royalties on an approved product.

The deal structure puts $1.2 billion upfront and up to $1.1 billion in contingent payments tied to OLN324 milestones. J&J expects to close the transaction by the end of this year.

What does OLN324 bring to J&J's portfolio?

Ollin's lead candidate, OLN324, is a bispecific antibody that blocks VEGF and Ang2 — the same two targets as Roche's Vabysmo, which holds approvals in wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Austin, Texas-based Ollin has claimed its molecule could be best in class, and the Phase 1b data give that claim a foundation.

The proof-of-concept test compared OLN324 head to head against Vabysmo. Delivered by intravitreal injection, OLN324 produced faster and greater structural changes in the eye and numerically better vision improvement at 20 weeks in both AMD and DME. Ollin presented the results in July at the annual meeting of the American Society of Retina Specialists.

Kip Connor, vice president and ophthalmology disease area stronghold leader at J&J, said the data support a differentiated profile. "The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients," Connor said in the acquisition announcement. He added that the drug has potential to achieve stronger and more sustained disease control.

For retinal specialists and payers, the operative question is durability: longer intervals between injections would change practice economics and positioning against Vabysmo, which built its market share on extended dosing.

Who runs the Phase 3, and who pays for it?

Ollin had been preparing a Phase 3 program in wet AMD and DME before the acquisition. J&J now takes responsibility for the pivotal trials, and the financing is already arranged. The Blackstone Life Sciences agreement, struck separately from the buyout, commits up to $750 million to late-stage clinical development, with returns structured as regulatory and sales milestone payments plus royalties on sales of an approved product.

Ollin formed in 2023 and formally launched last year. Arch Venture Partners, Mubadala Capital and Monograph Capital led a $100 million financing to build the company. In June, TCGX and Arch co-led a $330 million Series B to support the Phase 3 tests.

The science has an external origin. China-based Innovent Biologics discovered OLN324, and the two companies collaborated on clinical development. That lineage matters for supply chain and manufacturing planning as the program scales into registrational trials.

Why the deal marks a reset for J&J in vision disorders

J&J's main presence in ophthalmology runs through its medtech segment — contact lenses and products for cataract and refractive procedures. Its pharma-side push into vision disorders gene therapy failed. Last year, a gene therapy for X-linked retinitis pigmentosa linked to RPGR mutations missed its Phase 3 endpoint. MeiraGtx, the therapy's original developer, reacquired global rights to the asset earlier this year.

The Ollin acquisition replaces that gene therapy setback with a near-term small-molecule-style play: a validated target pair, head-to-head data against the market leader, and a Phase 3 program ready to launch under an established development and commercial infrastructure.

What arrives beyond OLN324?

The buyout also brings OLN102, a second bispecific antibody that blocks TSHR and IGF-1R to treat thyroid eye disorder. VelaVigo discovered the molecule and has developed it in partnership with Ollin. When Ollin announced its Series B round, the biotech said it planned to advance OLN102 into the clinic this year.

For J&J portfolio planners, the deal adds a funded Phase 3 asset in a multibillion-dollar retinal market plus an early clinical TED program — and puts a second VEGF/Ang2 bispecific on a collision course with Roche.

via businesswire.com (Original)

Share this article:

More from Olivia Hart

Olivia Hart

Show full bio

Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.

13 articles

Linked filings

  1. V-5496
  2. P-6323
  3. C-9698
  4. K-7275
  5. C-4460